RSLS
Income statement / Annual
Last year (2023), ReShape Lifesciences Inc.'s total revenue was $8.68 M,
a decrease of 22.79% from the previous year.
In 2023, ReShape Lifesciences Inc.'s net income was -$11.39 M.
See ReShape Lifesciences Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$8.68 M |
$11.24 M |
$13.60 M |
$11.30 M |
$15.09 M |
$606,710.00 |
$1.29 M |
$786,660.00 |
$292,000.00 |
$0.00 |
Cost of Revenue |
$3.13 M
|
$4.44 M
|
$5.25 M
|
$5.04 M
|
$5.78 M
|
$164,299.00
|
$936,386.00
|
$431,476.00
|
$125,000.00
|
$0.00
|
Gross Profit |
$5.55 M
|
$6.80 M
|
$8.35 M
|
$6.26 M
|
$9.31 M
|
$442,411.00
|
$350,768.00
|
$355,184.00
|
$167,000.00
|
$0.00
|
Gross Profit Ratio |
0.64
|
0.61
|
0.61
|
0.55
|
0.62
|
0.73
|
0.27
|
0.45
|
0.57
|
0
|
Research and Development Expenses |
$2.32 M
|
$2.54 M
|
$2.52 M
|
$3.50 M
|
$3.12 M
|
$5.72 M
|
$5.78 M
|
$5.17 M
|
$8.14 M
|
$11.03 M
|
General & Administrative Expenses |
$10.32 M
|
$17.25 M
|
$24.41 M
|
$10.53 M
|
$17.22 M
|
$19.26 M
|
$25.98 M
|
$0.00
|
$0.00
|
$0.00
|
Selling & Marketing Expenses |
$7.55 M
|
$14.09 M
|
$9.17 M
|
$4.69 M
|
$4.85 M
|
$5.24 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$17.87 M
|
$31.34 M
|
$33.58 M
|
$15.22 M
|
$22.07 M
|
$19.26 M
|
$25.98 M
|
$17.98 M
|
$19.89 M
|
$14.56 M
|
Other Expenses |
$0.00
|
$11,000.00
|
$23.50 M
|
$306,000.00
|
-$1.34 M
|
-$10,643.00
|
-$652.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$20.19 M
|
$33.88 M
|
$36.10 M
|
$18.72 M
|
$25.19 M
|
$24.98 M
|
$31.76 M
|
$23.15 M
|
$28.03 M
|
$25.59 M
|
Cost And Expenses |
$23.32 M
|
$38.32 M
|
$41.35 M
|
$23.76 M
|
$30.98 M
|
$25.15 M
|
$32.70 M
|
$23.58 M
|
$28.16 M
|
$25.59 M
|
Interest Income |
$0.00
|
$113,000.00
|
$832,000.00
|
$2.05 M
|
$451,000.00
|
$0.00
|
$1,066.00
|
$5,837.00
|
$1,819.00
|
$3,331.00
|
Interest Expense |
$0.00
|
$113,000.00
|
$832,000.00
|
$2.05 M
|
$451,000.00
|
$12,378.00
|
$3,874.00
|
$4.10 M
|
$939,182.00
|
$530,222.00
|
Depreciation & Amortization |
$154,000.00
|
$2.15 M
|
$1.97 M
|
$1.67 M
|
$894,000.00
|
$581,000.00
|
$330,000.00
|
$192,000.00
|
$188,606.00
|
$188,904.00
|
EBITDA |
-$14.49 M |
-$24.93 M |
-$60.62 M |
-$18.10 M |
-$17.22 M |
-$36.97 M |
-$34.39 M |
-$19.51 M |
-$27.68 M |
-$25.40 M |
EBITDA Ratio |
-1.67
|
-2.22
|
-2.04
|
-1.1
|
-1.14
|
-39.74
|
-24.4
|
-28.97
|
-103.54
|
0
|
Operating Income Ratio |
-1.69
|
-2.41
|
-2.04
|
-1.1
|
-1.05
|
-63.53
|
-24.4
|
-28.98
|
-95.43
|
0
|
Total Other Income/Expenses Net |
$3.30 M
|
-$4.68 M
|
-$12.17 M
|
-$9.35 M
|
-$50.64 M
|
-$167,731.00
|
-$1.37 M
|
-$565,217.00
|
$2.37 M
|
-$535,725.00
|
Income Before Tax |
-$11.34 M
|
-$46.59 M
|
-$62.04 M
|
-$21.81 M
|
-$75.10 M
|
-$38.71 M
|
-$36.13 M
|
-$23.36 M
|
-$25.50 M
|
-$26.13 M
|
Income Before Tax Ratio |
-1.31
|
-4.15
|
-4.56
|
-1.93
|
-4.98
|
-63.81
|
-28.07
|
-29.7
|
-87.33
|
0
|
Income Tax Expense |
$52,000.00
|
-$380,000.00
|
-$106,000.00
|
-$181,000.00
|
-$893,000.00
|
-$3.45 M
|
-$2.31 M
|
$3.96 M
|
-$2.56 M
|
$347,096.00
|
Net Income |
-$11.39 M
|
-$46.21 M
|
-$61.93 M
|
-$21.63 M
|
-$74.21 M
|
-$81.15 M
|
-$33.82 M
|
-$23.36 M
|
-$25.50 M
|
-$26.13 M
|
Net Income Ratio |
-1.31
|
-4.11
|
-4.55
|
-1.91
|
-4.92
|
-133.76
|
-26.27
|
-29.7
|
-87.33
|
0
|
EPS |
-110.88 |
-6316.2 |
-16438.36 |
-48193.94 |
-137166.52 |
-370876.36 |
-176008.54 |
-481393.62 |
-132819.42 |
0 |
EPS Diluted |
-110.88 |
-6316.2 |
-16438.36 |
-48193.94 |
-137166.52 |
-370876.36 |
-176008.54 |
-481393.62 |
-132819.42 |
0 |
Weighted Average Shares Out |
$102,699.00
|
$7,317.07
|
$3,767.62
|
$1,346.43
|
$1,623.00
|
$218.81
|
$192.14
|
$48.53
|
$191.98
|
$0.00
|
Weighted Average Shares Out Diluted |
$102,699.00
|
$7,317.07
|
$3,767.62
|
$1,346.43
|
$1,623.00
|
$218.81
|
$192.14
|
$48.53
|
$191.98
|
$0.00
|
Link |
|
|
|
|
|
|
|
|
|
|